A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
The identification of molecular agents inhibiting specific functions in cancer cells
progression is considered as one of the most successful plans in cancer treatment. The …
progression is considered as one of the most successful plans in cancer treatment. The …
Lung cancer: current therapies and new targeted treatments
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
[HTML][HTML] Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
Y Hu, X Sui, F Song, Y Li, K Li, Z Chen, F Yang… - Nature …, 2021 - nature.com
While the potential of patient-derived organoids (PDOs) to predict patients' responses to anti-
cancer treatments has been well recognized, the lengthy time and the low efficiency in …
cancer treatments has been well recognized, the lengthy time and the low efficiency in …
[HTML][HTML] First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …
[HTML][HTML] Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino… - … England Journal of …, 2017 - Mass Medical Soc
Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
[HTML][HTML] Non-small cell lung cancer: current treatment and future advances
C Zappa, SA Mousa - Translational lung cancer research, 2016 - ncbi.nlm.nih.gov
Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …
Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update
Purpose To provide evidence-based recommendations to oncology clinicians, patients,
family and friend caregivers, and palliative care specialists to update the 2012 American …
family and friend caregivers, and palliative care specialists to update the 2012 American …
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
N Hanna, D Johnson, S Temin, S Baker Jr… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …